RAGNAR
22 Dec 2020
RAGNAR
NCT04083976
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Janssen Research & Development LLC
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2019-11-19 |
Anticipated End Date | 2025-07-14 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | Dr Chris Karapetis |
Recruitment Status | Not Yet Recruiting |